Skip to main content
Top
Published in: BMC Gastroenterology 1/2010

Open Access 01-12-2010 | Research article

Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor

Authors: Tsutomu Fujii, Bryan C Fuchs, Suguru Yamada, Gregory Y Lauwers, Yakup Kulu, Jonathan M Goodwin, Michael Lanuti, Kenneth K Tanabe

Published in: BMC Gastroenterology | Issue 1/2010

Login to get access

Abstract

Background

In the setting of chronic liver injury in humans, epidermal growth factor (EGF) and EGF receptor (EGFR) are up-regulated and have been proposed to have vital roles in both liver regeneration and development of hepatocellular carcinoma (HCC). Chronic liver injury also leads to hepatic stellate cell (HSC) differentiation and a novel subpopulation of HSCs which express CD133 and exhibit properties of progenitor cells has been described in rats. The carbon tetrachloride (CCl4)-induced mouse model has been historically relied upon to study liver injury and regeneration. We exposed mice to CCl4 to assess whether EGF and CD133+ HSCs are up-regulated in chronically injured liver.

Methods

CCl4 in olive oil was administered to strain A/J mice three times per week by oral gavage.

Results

Multiple well-differentiated HCCs were found in all livers after 15 weeks of CCl4 treatment. Notably, HCCs developed within the setting of fibrosis and not cirrhosis. CD133 was dramatically up-regulated after CCl4 treatment, and increased expression of desmin and glial fibrillary acidic protein, representative markers of HSCs, was also observed. EGF expression significantly decreased, contrary to observations in humans, whereas the expression of amphiregulin, another EGFR ligand, was significantly increased.

Conclusions

Species-specific differences exist with respect to the histopathological and molecular pathogenesis of chronic liver disease. CCl4-induced chronic liver injury in A/J mice has important differences compared to human cirrhosis leading to HCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007, 132: 2557-76. 10.1053/j.gastro.2007.04.061.CrossRefPubMed El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007, 132: 2557-76. 10.1053/j.gastro.2007.04.061.CrossRefPubMed
2.
go back to reference Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, Pagliaro L: Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991, 36: 962-72. 10.1007/BF01297149.CrossRefPubMed Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, Pagliaro L: Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991, 36: 962-72. 10.1007/BF01297149.CrossRefPubMed
3.
go back to reference Pierce RA, Glaug MR, Greco RS, Mackenzie JW, Boyd CD, Deak SB: Increased procollagen mRNA levels in carbon tetrachloride-induced liver fibrosis in rats. J Biol Chem. 1987, 262: 1652-8.PubMed Pierce RA, Glaug MR, Greco RS, Mackenzie JW, Boyd CD, Deak SB: Increased procollagen mRNA levels in carbon tetrachloride-induced liver fibrosis in rats. J Biol Chem. 1987, 262: 1652-8.PubMed
4.
go back to reference Perez Tamayo R: Is cirrhosis of the liver experimentally produced by CCl4 and adequate model of human cirrhosis?. Hepatology. 1983, 3: 112-20. 10.1002/hep.1840030118.CrossRefPubMed Perez Tamayo R: Is cirrhosis of the liver experimentally produced by CCl4 and adequate model of human cirrhosis?. Hepatology. 1983, 3: 112-20. 10.1002/hep.1840030118.CrossRefPubMed
5.
go back to reference Shi J, Aisaki K, Ikawa Y, Wake K: Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am J Pathol. 1998, 153: 515-25.CrossRefPubMedPubMedCentral Shi J, Aisaki K, Ikawa Y, Wake K: Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am J Pathol. 1998, 153: 515-25.CrossRefPubMedPubMedCentral
6.
go back to reference Manibusan MK, Odin M, Eastmond DA: Postulated carbon tetrachloride mode of action: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2007, 25: 185-209.CrossRefPubMed Manibusan MK, Odin M, Eastmond DA: Postulated carbon tetrachloride mode of action: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2007, 25: 185-209.CrossRefPubMed
7.
go back to reference Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000, 275: 2247-50. 10.1074/jbc.275.4.2247.CrossRefPubMed Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000, 275: 2247-50. 10.1074/jbc.275.4.2247.CrossRefPubMed
8.
go back to reference Wu J, Zern MA: Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol. 2000, 35: 665-72. 10.1007/s005350070045.CrossRefPubMed Wu J, Zern MA: Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol. 2000, 35: 665-72. 10.1007/s005350070045.CrossRefPubMed
9.
go back to reference Kordes C, Sawitza I, Muller-Marbach A, Ale-Agha N, Keitel V, Klonowski-Stumpe H, Haussinger D: CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun. 2007, 352: 410-7. 10.1016/j.bbrc.2006.11.029.CrossRefPubMed Kordes C, Sawitza I, Muller-Marbach A, Ale-Agha N, Keitel V, Klonowski-Stumpe H, Haussinger D: CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun. 2007, 352: 410-7. 10.1016/j.bbrc.2006.11.029.CrossRefPubMed
10.
go back to reference Natarajan A, Wagner B, Sibilia M: The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA. 2007, 104: 17081-6. 10.1073/pnas.0704126104.CrossRefPubMedPubMedCentral Natarajan A, Wagner B, Sibilia M: The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA. 2007, 104: 17081-6. 10.1073/pnas.0704126104.CrossRefPubMedPubMedCentral
11.
go back to reference Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC: Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. Jama. 2008, 299: 53-60. 10.1001/jama.2007.65.CrossRefPubMed Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC: Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. Jama. 2008, 299: 53-60. 10.1001/jama.2007.65.CrossRefPubMed
12.
go back to reference Komuves LG, Feren A, Jones AL, Fodor E: Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem. 2000, 48: 821-30.CrossRefPubMed Komuves LG, Feren A, Jones AL, Fodor E: Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem. 2000, 48: 821-30.CrossRefPubMed
13.
go back to reference Sorkin A, Goh LK: Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2009, 315: 683-96. 10.1016/j.yexcr.2008.07.029.CrossRefPubMed Sorkin A, Goh LK: Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2009, 315: 683-96. 10.1016/j.yexcr.2008.07.029.CrossRefPubMed
14.
go back to reference Lai WH, Cameron PH, Wada I, Doherty JJ, Kay DG, Posner BI, Bergeron JJ: Ligand-mediated internalization, recycling, and downregulation of the epidermal growth factor receptor in vivo. J Cell Biol. 109: 2741-9. 10.1083/jcb.109.6.2741. Lai WH, Cameron PH, Wada I, Doherty JJ, Kay DG, Posner BI, Bergeron JJ: Ligand-mediated internalization, recycling, and downregulation of the epidermal growth factor receptor in vivo. J Cell Biol. 109: 2741-9. 10.1083/jcb.109.6.2741.
15.
go back to reference Mead JE, Fausto N: Transforming growth factor alpha may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci USA. 1989, 86: 1558-62. 10.1073/pnas.86.5.1558.CrossRefPubMedPubMedCentral Mead JE, Fausto N: Transforming growth factor alpha may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci USA. 1989, 86: 1558-62. 10.1073/pnas.86.5.1558.CrossRefPubMedPubMedCentral
16.
go back to reference Yokoi Y, Namihisa T, Kuroda H, Komatsu I, Miyazaki A, Watanabe S, Usui K: Immunocytochemical detection of desmin in fat-storing cells (Ito cells). Hepatology. 1984, 4: 709-14. 10.1002/hep.1840040425.CrossRefPubMed Yokoi Y, Namihisa T, Kuroda H, Komatsu I, Miyazaki A, Watanabe S, Usui K: Immunocytochemical detection of desmin in fat-storing cells (Ito cells). Hepatology. 1984, 4: 709-14. 10.1002/hep.1840040425.CrossRefPubMed
17.
go back to reference Zalatnai A, Lapis K: Simultaneous induction of liver cirrhosis and hepatocellular carcinomas in F-344 rats: establishment of a short hepatocarcinogenesis model. Exp Toxicol Pathol. 1994, 46: 215-22.CrossRefPubMed Zalatnai A, Lapis K: Simultaneous induction of liver cirrhosis and hepatocellular carcinomas in F-344 rats: establishment of a short hepatocarcinogenesis model. Exp Toxicol Pathol. 1994, 46: 215-22.CrossRefPubMed
18.
go back to reference Ferencz V, Horvath C, Kari B, Gaal J, Meszaros S, Wolf Z, Hegedus D, Horvath A, Folhoffer A, Szalay F: Bone disorders in experimentally induced liver disease in growing rats. World J Gastroenterol. 2005, 11: 7169-73.CrossRefPubMedPubMedCentral Ferencz V, Horvath C, Kari B, Gaal J, Meszaros S, Wolf Z, Hegedus D, Horvath A, Folhoffer A, Szalay F: Bone disorders in experimentally induced liver disease in growing rats. World J Gastroenterol. 2005, 11: 7169-73.CrossRefPubMedPubMedCentral
19.
go back to reference Edwards JE, Dalton AJ: Induction of cirrhosis of the liver and of hepatomas in mice with carbon tetrachloride. J Natl Cancer Inst. 1942, 3: 19-41. Edwards JE, Dalton AJ: Induction of cirrhosis of the liver and of hepatomas in mice with carbon tetrachloride. J Natl Cancer Inst. 1942, 3: 19-41.
20.
go back to reference Stowell RE, Lee CS, Tsuboi KK, Villasana A: Histochemical and microchemical changes in experimental cirrhosis and hepatoma formation in mice by carbon tetrachloride. Cancer Res. 1951, 11: 345-54.PubMed Stowell RE, Lee CS, Tsuboi KK, Villasana A: Histochemical and microchemical changes in experimental cirrhosis and hepatoma formation in mice by carbon tetrachloride. Cancer Res. 1951, 11: 345-54.PubMed
21.
go back to reference Belyaev ND, Budker VG, Deriy LV, Smolenskaya IA, Subbotin VM: Liver plasma membrane-associated fibroblast growth: stimulatory and inhibitory activities during experimental cirrhosis. Hepatology. 1992, 15: 525-31. 10.1002/hep.1840150327.CrossRefPubMed Belyaev ND, Budker VG, Deriy LV, Smolenskaya IA, Subbotin VM: Liver plasma membrane-associated fibroblast growth: stimulatory and inhibitory activities during experimental cirrhosis. Hepatology. 1992, 15: 525-31. 10.1002/hep.1840150327.CrossRefPubMed
22.
go back to reference Terai S, Sakaida I, Yamamoto N, Omori K, Watanabe T, Ohata S, Katada T, Miyamoto K, Shinoda K, Nishina H, Okita K: An in vivo model for monitoring trans-differentiation of bone marrow cells into functional hepatocytes. J Biochem. 2003, 134: 551-8. 10.1093/jb/mvg173.CrossRefPubMed Terai S, Sakaida I, Yamamoto N, Omori K, Watanabe T, Ohata S, Katada T, Miyamoto K, Shinoda K, Nishina H, Okita K: An in vivo model for monitoring trans-differentiation of bone marrow cells into functional hepatocytes. J Biochem. 2003, 134: 551-8. 10.1093/jb/mvg173.CrossRefPubMed
23.
go back to reference Xue F, Takahara T, Yata Y, Kuwabara Y, Shinno E, Nonome K, Minemura M, Takahara S, Li X, Yamato E, Watanabe A: Hepatocyte growth factor gene therapy accelerates regeneration in cirrhotic mouse livers after hepatectomy. Gut. 2003, 52: 694-700. 10.1136/gut.52.5.694.CrossRefPubMedPubMedCentral Xue F, Takahara T, Yata Y, Kuwabara Y, Shinno E, Nonome K, Minemura M, Takahara S, Li X, Yamato E, Watanabe A: Hepatocyte growth factor gene therapy accelerates regeneration in cirrhotic mouse livers after hepatectomy. Gut. 2003, 52: 694-700. 10.1136/gut.52.5.694.CrossRefPubMedPubMedCentral
24.
go back to reference Black D, Bird MA, Samson CM, Lyman S, Lange PA, Schrum LW, Qian T, Lemasters JJ, Brenner DA, Rippe RA, Behrns KE: Primary cirrhotic hepatocytes resist TGFbeta-induced apoptosis through a ROS-dependent mechanism. J Hepatol. 2004, 40: 942-51. 10.1016/S0168-8278(04)00128-X.CrossRefPubMed Black D, Bird MA, Samson CM, Lyman S, Lange PA, Schrum LW, Qian T, Lemasters JJ, Brenner DA, Rippe RA, Behrns KE: Primary cirrhotic hepatocytes resist TGFbeta-induced apoptosis through a ROS-dependent mechanism. J Hepatol. 2004, 40: 942-51. 10.1016/S0168-8278(04)00128-X.CrossRefPubMed
25.
go back to reference Ozdogan M, Ersoy E, Dundar K, Albayrak L, Devay S, Gundogdu H: Beneficial effect of hyperbaric oxygenation on liver regeneration in cirrhosis. J Surg Res. 2005, 129: 260-4. 10.1016/j.jss.2005.06.036.CrossRefPubMed Ozdogan M, Ersoy E, Dundar K, Albayrak L, Devay S, Gundogdu H: Beneficial effect of hyperbaric oxygenation on liver regeneration in cirrhosis. J Surg Res. 2005, 129: 260-4. 10.1016/j.jss.2005.06.036.CrossRefPubMed
26.
go back to reference Kim KH, Kim HC, Hwang MY, Oh HK, Lee TS, Chang YC, Song HJ, Won NH, Park KK: The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis. Biochem Biophys Res Commun. 2006, 343: 1072-8. 10.1016/j.bbrc.2006.03.087.CrossRefPubMed Kim KH, Kim HC, Hwang MY, Oh HK, Lee TS, Chang YC, Song HJ, Won NH, Park KK: The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis. Biochem Biophys Res Commun. 2006, 343: 1072-8. 10.1016/j.bbrc.2006.03.087.CrossRefPubMed
27.
go back to reference Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA: Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science. 2000, 287: 1253-8. 10.1126/science.287.5456.1253.CrossRefPubMed Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA: Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science. 2000, 287: 1253-8. 10.1126/science.287.5456.1253.CrossRefPubMed
28.
go back to reference Ishiki Y, Ohnishi H, Muto Y, Matsumoto K, Nakamura T: Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology. 1992, 16: 1227-35.PubMed Ishiki Y, Ohnishi H, Muto Y, Matsumoto K, Nakamura T: Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology. 1992, 16: 1227-35.PubMed
29.
go back to reference Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Clergue F, Poupon R, Barbu V, Rosmorduc O: Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005, 41: 307-14. 10.1002/hep.20538.CrossRefPubMed Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Clergue F, Poupon R, Barbu V, Rosmorduc O: Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005, 41: 307-14. 10.1002/hep.20538.CrossRefPubMed
30.
go back to reference Kuriyama S, Yokoyama F, Inoue H, Takano J, Ogawa M, Kita Y, Yoshiji H, Deguchi A, Kimura Y, Himoto T, Yoneyama H, Kurokohchi K, Masaki T, Uchida N, Watanabe S: Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-beta1 in hepatofibrogenesis of a rat cirrhosis model. Int J Mol Med. 2007, 19: 317-24.PubMed Kuriyama S, Yokoyama F, Inoue H, Takano J, Ogawa M, Kita Y, Yoshiji H, Deguchi A, Kimura Y, Himoto T, Yoneyama H, Kurokohchi K, Masaki T, Uchida N, Watanabe S: Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-beta1 in hepatofibrogenesis of a rat cirrhosis model. Int J Mol Med. 2007, 19: 317-24.PubMed
31.
go back to reference El-Bassiouni A, Nosseir M, Zoheiry M, El-Ahwany E, Ghali A, El-Bassiouni N: Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. Apmis. 2006, 114: 420-7. 10.1111/j.1600-0463.2006.apm_323.x.CrossRefPubMed El-Bassiouni A, Nosseir M, Zoheiry M, El-Ahwany E, Ghali A, El-Bassiouni N: Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. Apmis. 2006, 114: 420-7. 10.1111/j.1600-0463.2006.apm_323.x.CrossRefPubMed
32.
go back to reference Fausto N, Laird AD, Webber EM: Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. Faseb J. 1995, 9: 1527-36.PubMed Fausto N, Laird AD, Webber EM: Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. Faseb J. 1995, 9: 1527-36.PubMed
33.
go back to reference Nagano K, Umeda Y, Saito M, Nishizawa T, Ikawa N, Arito H, Yamamoto S, Fukushima S: Thirteen-week inhalation toxicity of carbon tetrachloride in rats and mice. J Occup Health. 2007, 49: 249-59. 10.1539/joh.49.249.CrossRefPubMed Nagano K, Umeda Y, Saito M, Nishizawa T, Ikawa N, Arito H, Yamamoto S, Fukushima S: Thirteen-week inhalation toxicity of carbon tetrachloride in rats and mice. J Occup Health. 2007, 49: 249-59. 10.1539/joh.49.249.CrossRefPubMed
34.
go back to reference Desmouliere A: Hepatic stellate cells: the only cells involved in liver fibrogenesis? A dogma challenged. Gastroenterology. 2007, 132: 2059-62. 10.1053/j.gastro.2007.03.075.CrossRefPubMed Desmouliere A: Hepatic stellate cells: the only cells involved in liver fibrogenesis? A dogma challenged. Gastroenterology. 2007, 132: 2059-62. 10.1053/j.gastro.2007.03.075.CrossRefPubMed
35.
go back to reference Noguchi S, Ohba Y, Oka T: Influence of epidermal growth factor on liver regeneration after partial hepatectomy in mice. J Endocrinol. 1991, 128: 425-31. 10.1677/joe.0.1280425.CrossRefPubMed Noguchi S, Ohba Y, Oka T: Influence of epidermal growth factor on liver regeneration after partial hepatectomy in mice. J Endocrinol. 1991, 128: 425-31. 10.1677/joe.0.1280425.CrossRefPubMed
36.
go back to reference Jones DE, Tran-Patterson R, Cui DM, Davin D, Estell KP, Miller DM: Epidermal growth factor secreted from the salivary gland is necessary for liver regeneration. Am J Physiol. 1995, 268: G872-8.PubMed Jones DE, Tran-Patterson R, Cui DM, Davin D, Estell KP, Miller DM: Epidermal growth factor secreted from the salivary gland is necessary for liver regeneration. Am J Physiol. 1995, 268: G872-8.PubMed
37.
go back to reference Daveau M, Scotte M, Francois A, Coulouarn C, Ros G, Tallet Y, Hiron M, Hellot MF, Salier JP: Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog. 2003, 36: 130-41. 10.1002/mc.10103.CrossRefPubMed Daveau M, Scotte M, Francois A, Coulouarn C, Ros G, Tallet Y, Hiron M, Hellot MF, Salier JP: Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog. 2003, 36: 130-41. 10.1002/mc.10103.CrossRefPubMed
38.
go back to reference Perugorria MJ, Latasa MU, Nicou A, Cartagena-Lirola H, Castillo J, Goñi S, Vespasiani-Gentilucci U, Zagami MG, Lotersztajn S, Prieto J, Berasain C, Avila MA: The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology. 2008, 48: 1251-61. 10.1002/hep.22437.CrossRefPubMed Perugorria MJ, Latasa MU, Nicou A, Cartagena-Lirola H, Castillo J, Goñi S, Vespasiani-Gentilucci U, Zagami MG, Lotersztajn S, Prieto J, Berasain C, Avila MA: The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology. 2008, 48: 1251-61. 10.1002/hep.22437.CrossRefPubMed
39.
go back to reference Tsuchiya A, Kamimura H, Takamura M, Yamagiwa S, Matsuda Y, Sato Y, Nomoto M, Ichida T, Aoyagi Y: Clinicopathological analysis of CD133 and NCAM human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas. Hepatol Res. 2009, 39: 1080-90. 10.1111/j.1872-034X.2009.00559.x.CrossRefPubMed Tsuchiya A, Kamimura H, Takamura M, Yamagiwa S, Matsuda Y, Sato Y, Nomoto M, Ichida T, Aoyagi Y: Clinicopathological analysis of CD133 and NCAM human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas. Hepatol Res. 2009, 39: 1080-90. 10.1111/j.1872-034X.2009.00559.x.CrossRefPubMed
40.
go back to reference Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL: Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA. 2000, 97: 14720-5. 10.1073/pnas.97.26.14720.CrossRefPubMedPubMedCentral Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL: Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA. 2000, 97: 14720-5. 10.1073/pnas.97.26.14720.CrossRefPubMedPubMedCentral
41.
go back to reference Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007, 132: 2542-56. 10.1053/j.gastro.2007.04.025.CrossRefPubMed Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007, 132: 2542-56. 10.1053/j.gastro.2007.04.025.CrossRefPubMed
42.
go back to reference Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007, 120: 1444-50. 10.1002/ijc.22476.CrossRefPubMed Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007, 120: 1444-50. 10.1002/ijc.22476.CrossRefPubMed
Metadata
Title
Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor
Authors
Tsutomu Fujii
Bryan C Fuchs
Suguru Yamada
Gregory Y Lauwers
Yakup Kulu
Jonathan M Goodwin
Michael Lanuti
Kenneth K Tanabe
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2010
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-10-79

Other articles of this Issue 1/2010

BMC Gastroenterology 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine